This post is a follow-up to my original Corcept deep dive covering the Korlym franchise, pipeline, legal risks, and valuation. I’d recommend reading that first.
The FDA approved relacorilant on March 25, 2026, under the brand name Lifyorli™, nearly four months ahead of the July 11 PDUFA date. Corcept had submitted a voluntary Assessment Aid to help structure the clinical data for review. The original deep dive assigned a 60% probability to approval and priced the base case at $57 per share. The binary event is resolved. The question now is what the launch looks like.
What the Label Says
The approved indication: Lifyorli in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Three details matter for the commercial opportunity:
No biomarker requirement. Any patient who meets the treatment history criteria is eligible. There is no genetic test or protein expression requirement. This is meaningful in oncology, where many approved drugs require companion diagnostic testing that creates prescribing friction.
The bevacizumab requirement limits the eligible population to patients who received at least one prior bevacizumab-containing regimen. Bevacizumab is NCCN-recommended as part of first-line and maintenance therapy for advanced ovarian cancer, so the majority of patients who develop platinum resistance will have received it. What percentage of the PROC population qualifies under the current label is the most important commercial question. I do not have a precise figure. Corcept’s Q1 2026 earnings call (expected late April) should provide commentary on the eligible population size.
Dosing is intermittent. Lifyorli is taken orally at 150mg on the day before, the day of, and the day after each nab-paclitaxel infusion, roughly nine days per 28-day cycle. This reduces total drug exposure relative to daily dosing and may affect the revenue per patient compared to a daily oral regimen.
The efficacy data confirmed by the FDA:
| Endpoint | Lifyorli + nab-paclitaxel | nab-paclitaxel alone |
|---|---|---|
| Median PFS (BICR) | 6.5 months (95% CI: 5.6, 7.4) | 5.5 months (95% CI: 3.9, 5.9) |
| PFS Hazard Ratio | 0.70 (95% CI: 0.54, 0.91; p=0.008) | — |
| Median OS | 16.0 months (95% CI: 13, 18.3) | 11.9 months (95% CI: 10, 13.8) |
| OS Hazard Ratio | 0.65 (95% CI: 0.51, 0.83; p=0.0004) | — |
The most common adverse reactions (≥20% incidence) include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite. The label includes contraindications for patients requiring corticosteroids for life-saving indications and warnings for neutropenia, severe infections, adrenal insufficiency, and embryo-fetal toxicity.
How the Thesis Changes
The original bear case ($19/share, 25% probability) was built on ovarian cancer rejection, Korlym erosion, pipeline stalls, and antitrust liability. The rejection scenario is closed. The bear case now reflects operational risk: slow launch, label constraints limiting the addressable population, continued Korlym generic pressure, and antitrust liability. Even in that scenario, Corcept is now a company with two approved drugs.
The $168 million in SG&A spent pre-building an oncology salesforce is validated. The original post noted that if approved, the spending positions Corcept to generate revenue immediately. The salesforce is in place, market access is built, and Lifyorli is approved.
What has not changed: Korlym generic erosion continues. The Cushing’s CRL is unresolved. The Teva antitrust trial is March 2027. Today’s approval addressed one risk, not all of them.
The pipeline expansion trials (BELLA in ovarian and endometrial cancer, TRIDENT in pancreatic cancer, STELLA in cervical cancer) are all testing relacorilant plus nab-paclitaxel using the same mechanism the FDA just approved. Each still needs to succeed on its own merits, but the regulatory precedent is established.
Updated Valuation
| Scenario | Assumptions | EV | Per Share |
|---|---|---|---|
| Bear | Slow launch, label limits peak to $500-800M, Korlym erodes to $400M by 2028, antitrust liability | $3.5B | $38 |
| Base | Lifyorli ramps to $1.0-1.5B peak, Korlym stabilizes at $600M, Cushing’s CRL resolved in 2027 | $7.0B | $71 |
| Bull | Label expansion beyond bevacizumab-pretreated, $2B+ Lifyorli, ALS Phase 3 succeeds, oncology platform validated | $12B+ | $118+ |
Per share values assume $532 million in cash added back to EV and approximately 106 million shares outstanding.
| Scenario | Probability | Per Share | Weighted |
|---|---|---|---|
| Bear | 20% | $38 | $7.60 |
| Base | 55% | $71 | $39.05 |
| Bull | 25% | $118 | $29.50 |
| Expected Value | $76 |
Three changes from the original analysis:
- Bear case floor rises from $19 to $38. Corcept now has an approved oncology drug in any scenario.
- Base case peak revenue trimmed from $1.5-2.0B to $1.0-1.5B to reflect the bevacizumab label restriction. If BELLA data or supplemental filings expand the label, this moves back up. (This could also be adjusted from Q1 earnings commentary on the eligible patient population size.)
- Bear case probability drops from 25% to 20%. The primary driver of the original bear case is gone.
The updated expected value is $76, up from $58. The biggest risk to this analysis is commercial execution: adoption rates, payer coverage decisions, and whether the bevacizumab restriction proves more limiting than expected. These will play out over quarters.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Q1 2026 earnings | First commentary on Lifyorli launch trajectory and eligible patient population | Late April 2026 |
| Lifyorli prescription volume | Will reveal whether the bevacizumab label restriction is a meaningful commercial constraint | Q2-Q3 2026 |
| EMA relacorilant decision | European approval for ovarian cancer | Q4 2026 |
| MONARCH MASH data readout | Phase 2b results for miricorilant in liver disease | End of 2026 |
| SYNERGY nenocorilant data | Phase 1b/2 safety and dosing data from immunotherapy combination | September 2026 |
| FDA path forward on Cushing’s CRL | Determines whether relacorilant can eventually replace Korlym | 2026 |
| Teva antitrust trial | Treble damages could be material | March 2027 |
| Dazucorilant ALS Phase 3 initiation | Confirms commitment after Phase 2 survival signal | 2026 |
Sources:
- 8-K filed March 25, 2026 (Lifyorli FDA approval)
- Corcept Therapeutics press release: FDA approves Lifyorli, March 25, 2026
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.